0 8 Positive positive JJ 9 12 and and CC 13 21 negative negative JJ 22 32 regulation regulation NN 33 35 of of IN 36 58 granulocyte-macrophage granulocyte-macrophage JJ 59 77 colony-stimulating colony-stimulating JJ 78 84 factor factor NN 85 93 promoter promoter NN 94 102 activity activity NN 103 105 by by IN 106 118 AML1-related aml1-related JJ 119 132 transcription transcription NN 133 139 factor factor NN 139 140 , , , 141 146 PEBP2 PEBP2 NNP 146 147 . . . 149 152 The the DT 153 175 granulocyte-macrophage granulocyte-macrophage JJ 176 194 colony-stimulating colony-stimulating JJ 195 201 factor factor NN 202 203 ( ( ( 203 209 GM-CSF GM-CSF NNP 209 210 ) ) ) 211 215 gene gene NN 216 224 promoter promoter NN 225 233 contains contain VBZ 234 235 a a DT 236 245 consensus consensus NN 246 254 sequence sequence NN 255 258 for for IN 259 262 the the DT 263 275 polyomavirus polyomavirus NN 276 284 enhancer enhancer NN 285 300 binding-protein binding-protein NN 301 302 2 2 CD 303 304 ( ( ( 304 309 PEBP2 pebp2 NN 309 310 ) ) ) 311 324 transcription transcription NN 325 331 factor factor NN 331 332 , , , 333 338 which which WDT 339 347 consists consist VBZ 348 350 of of IN 351 356 alpha alpha NN 357 360 and and CC 361 365 beta beta NN 366 374 subunits subunit NNS 374 375 . . . 376 381 There there EX 382 385 are be VBP 386 388 at at IN 389 394 least least JJS 395 398 two two CD 399 404 genes gene NNS 404 405 , , , 406 411 alpha alpha NN 412 413 A a NN 414 417 and and CC 418 423 alpha alpha NN 424 425 B b NN 425 426 , , , 427 435 encoding encode VBG 436 439 the the DT 440 445 alpha alpha NN 446 454 subunit. subunit. NN 455 460 alpha alpha NN 461 462 B B NNP 463 465 is be VBZ 466 469 the the DT 470 475 mouse mouse NN 476 485 homologue homologue NN 486 488 of of IN 489 494 human human JJ 495 499 AML1 aml1 NN 500 504 gene gene NN 505 513 detected detect VBN 514 516 at at IN 517 520 the the DT 521 532 breakpoints breakpoint NNS 533 535 of of IN 536 543 t(8;21) t(8;21) NNP 544 547 and and CC 548 555 t(3;21) t(3;21) NN 556 563 myeloid myeloid JJ 564 573 leukemias leukemia NNS 573 574 . . . 575 577 We we PRP 578 586 examined examine VBD 587 592 alpha alpha NN 593 595 A1 a1 NN 596 597 ( ( ( 597 599 an an DT 600 605 alpha alpha NN 606 612 A-gene a-gene JJ 613 620 product product NN 620 621 ) ) ) 622 625 and and CC 626 631 alpha alpha NN 632 634 B1 b1 NN 635 638 and and CC 639 644 alpha alpha NN 645 647 B2 b2 NN 648 649 ( ( ( 649 652 two two CD 653 658 alpha alpha NN 659 668 B-encoded b-encoded JJ 669 676 isomers isomer NNS 676 677 ) ) ) 678 681 for for IN 682 687 their their PRP$ 688 695 effects effect NNS 696 698 on on IN 699 702 the the DT 703 709 GM-CSF GM-CSF NNP 710 718 promoter promoter NN 718 719 . . . 720 725 PEBP2 pebp2 NN 726 731 alpha alpha NN 732 734 A1 a1 NN 734 735 , , , 736 741 alpha alpha NN 742 744 B1 b1 NN 744 745 , , , 746 749 and and CC 750 755 alpha alpha NN 756 758 B2 b2 NN 759 767 proteins protein NNS 768 773 bound bind VBD 774 777 the the DT 778 783 PEBP2 pebp2 NN 784 788 site site NN 789 795 within within IN 796 799 the the DT 800 805 mouse mouse NN 806 812 GM-CSF GM-CSF NNP 813 821 promoter promoter NN 821 822 . . . 823 828 PEBP2 pebp2 NN 829 834 alpha alpha NN 835 837 A1 a1 NN 838 841 and and CC 842 847 alpha alpha NN 848 850 B1 b1 NN 851 859 enhanced enhance VBD 860 863 the the DT 864 874 expression expression NN 875 877 of of IN 878 881 the the DT 882 888 GM-CSF GM-CSF NNP 889 904 promoter-driven promoter-driven JJ 905 913 reporter reporter NN 914 921 plasmid plasmid NN 922 924 in in IN 925 937 unstimulated unstimulated JJ 938 941 and and CC 942 967 12-O-tetradecanoylphorbol 12-o-tetradecanoylphorbol NN 968 1008 13-acetate/phytohemagglutinin-stimulated 13-acetate/phytohemagglutinin-stimulated JJ 1009 1014 human human JJ 1015 1021 Jurkat Jurkat NNP 1022 1023 T t NN 1024 1029 cells cell NNS 1029 1030 . . . 1031 1033 In in IN 1034 1042 contrast contrast NN 1042 1043 , , , 1044 1047 the the DT 1048 1056 promoter promoter NN 1057 1065 activity activity NN 1066 1069 was be VBD 1070 1080 suppressed suppress VBN 1081 1083 by by IN 1084 1089 alpha alpha NN 1090 1092 B2 b2 NN 1092 1093 . . . 1094 1106 Coexpression coexpression NN 1107 1109 of of IN 1110 1115 alpha alpha NN 1116 1118 B1 b1 NN 1119 1122 and and CC 1123 1128 alpha alpha NN 1129 1131 B2 b2 NN 1132 1138 showed show VBD 1139 1143 that that IN 1144 1147 the the DT 1148 1156 promoter promoter NN 1157 1165 activity activity NN 1166 1171 could could MD 1172 1174 be be VB 1175 1185 determined determine VBN 1186 1188 by by IN 1189 1192 the the DT 1193 1198 alpha alpha NN 1199 1207 B1/alpha B1/alpha NNP 1208 1210 B2 b2 NN 1211 1216 ratio ratio NN 1216 1217 . . . 1218 1224 Jurkat Jurkat NNP 1225 1229 cell cell NN 1230 1237 extract extract NN 1238 1247 contained contain VBD 1248 1253 PEBP2 pebp2 NN 1254 1266 site-binding site-binding JJ 1267 1277 protein(s) protein(s) NN 1278 1282 that that WDT 1283 1296 cross-reacted cross-reacte VBD 1297 1301 with with IN 1302 1311 antimouse antimouse JJ 1312 1317 alpha alpha NN 1318 1320 A1 a1 NN 1321 1331 antibodies antibody NNS 1331 1332 . . . 1333 1341 Northern Northern NNP 1342 1346 blot blot NN 1347 1355 analysis analysis NN 1356 1365 indicated indicate VBD 1366 1369 the the DT 1370 1380 expression expression NN 1381 1383 of of IN 1384 1389 human human JJ 1390 1395 PEBP2 pebp2 NN 1396 1401 alpha alpha NN 1402 1403 A A NNP 1403 1404 , , , 1405 1410 alpha alpha NN 1411 1412 B B NNP 1413 1414 ( ( ( 1414 1418 AML1 AML1 NNP 1418 1419 ) ) ) 1419 1420 , , , 1421 1424 and and CC 1425 1429 beta beta NN 1430 1435 genes gene NNS 1436 1438 in in IN 1439 1445 Jurkat Jurkat NNP 1446 1451 cells cell NNS 1451 1452 . . . 1453 1461 Although although IN 1462 1469 further further JJ 1470 1477 studies study NNS 1478 1481 are be VBP 1482 1490 required require VBN 1491 1493 to to TO 1494 1503 determine determine VB 1504 1507 the the DT 1508 1515 precise precise JJ 1516 1520 role role NN 1521 1523 of of IN 1524 1529 PEBP2 pebp2 NN 1530 1532 in in IN 1533 1536 the the DT 1537 1543 GM-CSF GM-CSF NNP 1544 1552 promoter promoter NN 1553 1561 activity activity NN 1561 1562 , , , 1563 1566 the the DT 1567 1574 present present JJ 1575 1583 findings finding NNS 1584 1593 suggested suggest VBD 1594 1597 the the DT 1598 1608 importance importance NN 1609 1611 of of IN 1612 1615 the the DT 1616 1624 relative relative JJ 1625 1630 ratio ratio NN 1631 1633 of of IN 1634 1643 different different JJ 1644 1649 PEBP2 pebp2 NN 1650 1658 isoforms isoform NNS 1659 1661 in in IN 1662 1672 regulating regulate VBG 1673 1676 the the DT 1677 1683 levels level NNS 1684 1686 of of IN 1687 1690 the the DT 1691 1699 promoter promoter NN 1700 1708 activity activity NN 1708 1709 . . .